THE CHALLENGES OF PPIS IN GENERAL PRACTICE: ADDRESSING MISUSE AND RESEARCH GAPS
DOI:
https://doi.org/10.63501/xdferv75Keywords:
Proton pump inhibitors (PPIs), inappropriate prescribing, gastric cancer, deprescribing protocolsAbstract
Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders due to their potent acid-suppressing effects. However, increasing evidence highlights concerns regarding their long-term and often inappropriate use. This letter emphasizes the risks associated with sustained PPI therapy, including gastrointestinal infections, nutrient malabsorption, bone demineralization, and a potential link to gastric cancer. It also addresses issues such as over-the-counter availability, lack of public awareness, inconsistent drug interaction data, and habitual prescribing without clinical reevaluation. To mitigate these risks, the need for unified prescribing guidelines, standardized interaction databases, and evidence-based deprescribing protocols is underscored. Future research should focus on assessing self-medication trends, the effectiveness of targeted interventions, and the underlying causes of irrational PPI use to ensure safer pharmacological practices.
References
1. Tosetti, C., & Nanni, I. (2017). Use of proton pump inhibitors in general practice. World journal of gastrointestinal pharmacology and therapeutics, 8(3), 180–185. https://doi.org/10.4292/wjgpt.v8.i3.180
2. Shin, J. M., & Sachs, G. (2008). Pharmacology of proton pump inhibitors. Current gastroenterology reports, 10(6), 528–534. https://doi.org/10.1007/s11894-008-0098-4
3. Abrahami, D., McDonald, E. G., Schnitzer, M. E., Barkun, A. N., Suissa, S., & Azoulay, L. (2022). Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut, 71(1), 16–24. https://doi.org/10.1136/gutjnl-2021-325097
4. Jarbøl, D. E., Lykkegaard, J., Hansen, J. M., Munck, A., & Haastrup, P. F. (2019). Prescribing of proton-pump inhibitors: auditing the management and reasons for prescribing in Danish general practice. Family practice, 36(6), 758–764. https://doi.org/10.1093/fampra/cmz025
5. Martin, R. M., Dunn, N. R., Freemantle, S., & Shakir, S. (2000). The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. British journal of clinical pharmacology, 50(4), 366–372. https://doi.org/10.1046/j.1365-2125.2000.00262.x
6. Trifirò, G., Corrao, S., Alacqua, M., Moretti, S., Tari, M., Caputi, A. P., Arcoraci, V., & UVEC Group (2006). Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. British journal of clinical pharmacology, 62(5), 582–590. https://doi.org/10.1111/j.1365-2125.2006.02687.x
7. Hungin, A. P., Rubin, G. P., & O'Flanagan, H. (1999). Co-prescription of H2 receptor blockers and proton pump inhibitors with warfarin in general practice. Postgraduate medical journal, 75(890), 721–722. https://doi.org/10.1136/pgmj.75.890.721
Downloads
Published
Issue
Section
License
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given to the author(s) and the source. To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0